This Article Full Text Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Services Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Duraker, N. Articles by Bati, B. Search for Related Content PubMed PubMed Citation Articles by Duraker, N. Articles by Bati, B.

Is there any Prognostically Different Subgroup among Patients with Stage IIIC (AnyTN3M0) Breast Carcinoma?

Nüvit Duraker, MD, Zeynep C. Çaynak, MD and Bakr Bat, MD

Fifth Department of Surgery, SSK Okmeydani Training Hospital, Istanbul, Turkey

Correspondence: Address correspondence and reprint requests to: Nüvit Duraker, MD; E-mail: nduraker{at}hotmail.com

Background: We investigated whether there are prognostically different subgroups among patients with stage IIIC (anyTN3M0) breast carcinoma.

Methods: The file records of 348 female patients operated for stage IIIC breast carcinoma were reviewed. The endpoint was disease recurrence.

Results: Patients with a T1, T2 or T3 tumor had significantly better disease-free survival (DFS) compared to those with a T4 tumor. In the patient group with T1,2,3N3M0 disease, the DFS was significantly better in patients with between 10 and 15 metastatic axillary lymph nodes, compared to patients with 16 or more metastatic lymph nodes (p = 0.0360) and in patients with a nodal ratio ( number of metastatic lymph nodes divided by number of removed nodes) less than or equal to 0.80, compared to patients with a nodal ratio greater than 0.80 (p = 0.0003). In the patient subgroup with between 10 and 15 metastatic lymph nodes, those with a nodal ratio greater than 0.80 had significantly worse DFS, whereas in the patient subgroup with 16 or more metastatic lymph nodes the nodal ratio had no prognostic significance. The DFS of patients with 10 to 15 positive lymph nodes and a nodal ratio of up to 0.80 was significantly better than that of both the patients with 10 to 15 positive lymph nodes and a nodal ratio greater than 0.80 (p = 0.0002), and the patients with 16 or more positive lymph nodes (p = 0.0002); survival of the latter two patient groups was similar.

Conclusions: Patients with T1,2,3N3M0 disease can be divided into prognostically different subgroups according to the number of metastatic lymph nodes in the axilla and the nodal ratio; in this way, different patient subgroups may be offered different treatment strategies.

Key Words: Breast cancer • TNM classification • Stage IIIC • Prognostic groups • Percentage of metastatic lymph nodes • Lymph node ratio

This article has been cited by other articles:

				N. Duraker Stage IIIC Breast Carcinoma and Prognostically Different Subgroups Ann. Surg. Oncol., June 1, 2008; 15(6): 1787 - 1787. [Full Text] [PDF]